Update on the Neuromuscular Stakeholders Meeting with FDA and NIH on AON Therapies
We
are pleased to announce that the live web streaming links are now
available for the FDA and NIH co-sponsored meeting Antisense
Oligonucleotide Therapies in Neuromuscular Diseases, taking place on
the 27th and 28th September, 2010 in Washington DC, USA.
The collaborative meeting will engage over 100 stakeholders from
multiple different neuromuscular diseases in which antisense
oligonucleotides (AONs) are being explored as a therapeutic strategy
(amyotrophic lateral sclerosis, Duchenne muscular dystrophy, myotonic
dystrophy and spinal muscular atrophy). It is sponsored by Children's
National Medical Centre, CureDuchenne, Foundation to Eradicate
Duchenne, MDA, Parent Project Muscular Dystrophy and TREAT-NMD.
The meeting will consist of four sessions:
- Toxicology and Preclinical Findings to Date
-
Clinical Trial Design / Endpoints
-
Patient Registries and Assessing Long-Term Outcomes
Its goal is to allow stakeholders to explore potential pathways
forward for the AONs with the eventual goal of creating a sound
scientific foundation for neuromuscular disease clinical development
programs. These initial discussions should be seen as first steps to
help pave the way for future discussions and collaborations.
The agenda will be available in the near future at Cure Duchenne.org website.
Over 100 stakeholders, consisting of researchers, academics,
industry and patient group representatives, will participate in the
meeting. In order to accommodate all those unable to attend the meeting
due to space limitations or geographical distance, the whole meeting
will be streamed on the web via dedicated web link(s).
To connect to the web streaming please use the links available here.
If you have any specific queries regarding this meeting please contact Emma Heslop (TREAT-NMD), Abby Bronson (CNMC) or John Porter (NIH).
For additional articles from Cure Duchenne Foundation, go to this link:http://www.cureduchenne.org/2010/09/update-on-the-neuromuscular-stakeholders-meeting-with-fda-and-nih-on-aon-therapies/
